Patents by Inventor Brett P. Giroir

Brett P. Giroir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE-STIMULATING PEPTIDES AND CHECKPOINT INHIBITORS, AND USES THEREOF FOR TREATING CANCER
    Publication number: 20190241660
    Abstract: Presented herein are immune-stimulating peptides and uses thereof for treating cancer. The immune-stimulating peptides can be used alone, or in combination with checkpoint inhibitors and other anti-cancer therapies. The immune-stimulating peptides can also be used for expanding T-cells in vitro or ex vivo, which expanded T-cells can then be used for adoptive cell therapy.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 8, 2019
    Inventors: Brett P. GIROIR, Clifford H. KERN, III, Carola LEUSCHNER
  • Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor
    Publication number: 20150017179
    Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 15, 2015
    Inventors: Brett P. GIROIR, Monte S. WILLIS, Vidal F. DE LA CRUZ, JR., Thais M. SIELECKI-DZURDZ
  • Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
    Patent number: 8747843
    Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: June 10, 2014
    Assignees: Baxter International, Inc., Baxter Healthcare SA, Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Monte S. Willis, Vidal F. De La Cruz, Jr., Thais M. Sielecki-Dzurdz
  • Macrophage migration inhibitory factor as a marker for cardiovascular risk
    Patent number: 7445886
    Abstract: Macrophage migration inhibitory factor (MIF) is a clinically useful biochemical marker of cardiovascular risk. Risk assessment includes the step of detecting in the blood of a person MIF concentration as a marker of cardiovascular risk for the person. The method may further comprise the step of assigning to the person a cardiovascular risk metric proportional to the MIF concentration, and/or prescribing for the person a cardiovascular treatment modality in accordance with the MIF concentration. The method is useful as a primary screen, and may be used in conjunction with or as a substitute for additional tests, such as a stress test, CRP assay, LDL assay, etc. The detecting step may be repeated over time intervals and/or treatment to monitor change in cardiovascular risk for the person over time and/or treatment.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: November 4, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Monty S. Willis, Timothy S. Church
  • Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor
    Publication number: 20080260723
    Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.
    Type: Application
    Filed: October 31, 2007
    Publication date: October 23, 2008
    Applicants: Cytokine PharmaSciences, Inc., Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Monte S. Willis, Vidal F. De La Cruz, Thais M. Sielecki-Dzurdz
  • Method of treating chronic cardiac disease
    Patent number: 7045501
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: May 16, 2006
    Assignee: XOMA Technology
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Method of treating chronic cardiac disease
    Publication number: 20030216312
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Application
    Filed: January 14, 2003
    Publication date: November 20, 2003
    Applicant: XOMA Technology Ltd.
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 6596691
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: July 22, 2003
    Assignee: XOMA Corporation
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Method of treating chronic cardiac disease
    Patent number: 6509317
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: January 21, 2003
    Assignees: Board of Regents, the University of Texas System, Xoma Technology Ltd.
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products for human meningococcemia
    Publication number: 20020103114
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Application
    Filed: November 30, 2000
    Publication date: August 1, 2002
    Applicant: XOMA Corporation and The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 6242418
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: June 5, 2001
    Assignees: Xoma Corporation, The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 5990086
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: November 23, 1999
    Assignee: Xoma Corporation
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 5888977
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: March 30, 1999
    Inventors: Brett P. Giroir, Patrick J. Scannon